KEGG DRUG: Insulin

DRUG: Insulin

Entry

D00085 Drug

Name

Insulin (JAN/USP)

Sequence

(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19)

Type

Peptide

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01802  Human insulin
   DG01798  Human insulin, fast-acting

Remark

Same as:

C00723

Efficacy

Antidiabetic, Insulin receptor agonist

Comment

Pancreas hormone

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

Interaction

Structure map

map07051

Antidiabetics

Brite

Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D00085  Insulin (JAN/USP)

Other DBs

CAS:

9004-10-8

PubChem:

ChEBI:

DrugBank:

NIKKAJI:

LinkDB

» Japanese version » Back

DRUG: Insulin human

Entry

D03230 Drug

Name

Insulin human (USP/INN);
Insulin human (genetical recombination) (JP18);
Insulin human (biosynthesis) (JAN);
Insulin human (synthesis) (JAN);
Humulin (TN)

Product

MYXREDLIN (Baxter Healthcare Corporation), HUMULIN (Eli Lilly and Company), AFREZZA (Mannkind Corporation)

Formula

C257H383N65O77S6

Exact mass

5803.6376

Mol weight

5807.5702

Sequence

Type

Peptide

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01802  Human insulin
   DG01798  Human insulin, fast-acting
Metabolizing enzyme inducer
DG01637  CYP1A2 inducer

Remark

Therapeutic category:

2492

ATC code:

A10AB01 A10AC01 A10AD01 A10AE01 A10AF01

Product:

D03230<JP/US>

Efficacy

Antidiabetic, Insulin receptor agonist

Disease

Diabetes mellitus [DS:H00408 H00409]

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

hsa04930

Type II diabetes mellitus

Interaction

CYP induction: CYP1A2 [HSA:1544]

Structure map

map07051

Antidiabetics

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AB Insulins and analogues for injection, fast-acting
     A10AB01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
    A10AC Insulins and analogues for injection, intermediate-acting
     A10AC01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
    A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
     A10AD01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
    A10AE Insulins and analogues for injection, long-acting
     A10AE01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
    A10AF Insulins and analogues for inhalation
     A10AF01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D03230  Insulin human (USP/INN); Insulin human (genetical recombination) (JP18); Insulin human (biosynthesis) (JAN); Insulin human (synthesis) (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D03230  Insulin human (USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
  D03230  Insulin human (genetical recombination)
  D03230  Insulin human (genetical recombination) injection
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D03230
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D03230

Other DBs

CAS:	11061-68-0

PubChem:

17397383

LinkDB

» Japanese version » Back

DRUG: Insulin glargine

Entry

D03250 Drug

Name

Insulin glargine (USAN/INN);
Insulin glargine (genetical recombination) (JP18);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 1] (JAN);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 2] (JAN);
Lantus (TN)

Product

TOUJEO (A-S Medication Solutions), LANTUS SOLOSTAR (A-S Medication Solutions), TOUJEO MAX (A-S Medication Solutions), LANTUS SOLOSTAR (A-S Medication Solutions), LANTUS (A-S Medication Solutions), BASAGLAR (Eli Lilly and Company), SEMGLEE (Mylan Specialty L.P.), LANTUS SOLOSTAR (REMEDYREPACK), INSULIN GLARGINE (Sanofi-Aventis U.S. LLC), INSULIN GLARGINE (sanofi-aventis U.S. LLC), INSULIN GLARGINE (sanofi-aventis U.S. LLC)

Formula

C267H404N72O78S6

Exact mass

6058.8184

Mol weight

6062.8903

Sequence

(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Gly
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr
Arg Arg
(Disulfide bridge: A6-A11, A7-B7, A20-B19)

Type

Peptide

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01801  Insulin analog
   DG01797  Insulin analog, long-acting
Metabolizing enzyme inducer
DG01637  CYP1A2 inducer

Remark

Therapeutic category:

2492

ATC code:

A10AE04

Product:

D03250<JP/US>

Product (mixture):

D11034<JP/US>

Efficacy

Antidiabetic, Insulin receptor agonist

Disease

Diabetes mellitus [DS:H00408 H00409]

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

hsa04930

Type II diabetes mellitus

Interaction

CYP induction: CYP1A2 [HSA:1544]

Structure map

map07051

Antidiabetics

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AE Insulins and analogues for injection, long-acting
     A10AE04 Insulin glargine
      D03250  Insulin glargine (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
  Insulins
   Insulin, Long-acting
    Insulin Glargine
     D03250  Insulin glargine (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D03250  Insulin glargine (USAN/INN); Insulin glargine (genetical recombination) (JP18); Insulin glargine (genetical recombination) [Insulin glargin biosimilar 1] (JAN); Insulin glargine (genetical recombination) [Insulin glargin biosimilar 2] (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D03250  Insulin glargine (USAN/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
  D03250  Insulin glargine (genetical recombination)
  D03250  Insulin glargine (genetical recombination) injection
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D03250
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D03250
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D03250
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D03250
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D03250

Other DBs

CAS:	160337-95-1

PubChem:

17397403

DrugBank:

DB00047

NIKKAJI:

J2.173.686D

LinkDB

» Japanese version » Back

DRUG: Insulin aspart

Entry

D04475 Drug

Name

Insulin aspart (USP/INN);
Insulin aspart (genetical recombination) (JP18);
Insulin aspart (genetical recombination) [Insulin aspart biosimilar 1] (JAN);
Insulin X 14;
NovoRapid (TN);
Novolog (TN)

Product

.INSULIN ASPART PROTAMINE AND INSULIN ASPART (A-S Medication Solutions), NOVOLOG MIX 70/30 (A-S Medication Solutions), INSULIN ASPART (A-S Medication Solutions), INSULIN ASPART (A-S Medication Solutions), NOVOLOG MIX 70/30 (A-S Medication Solutions), NOVOLOG (A-S Medication Solutions), NOVOLOG MIX 70/30 (A-S Medication Solutions), NOVOLOG MIX 70/30 (Novo Nordisk), INSULIN ASPART (Novo Nordisk Pharma), INSULIN ASPART PROTAMINE AND INSULIN ASPART (Novo Nordisk Pharma), NOVOLOG MIX 70/30 (REMEDYREPACK), INSULIN ASPART (REMEDYREPACK), NOVOLOG (REMEDYREPACK), FIASP (Novo Nordisk), WATER INJECTION (Novo Nordisk)

Formula

C256H381N65O79S6

Exact mass

5821.6118

Mol weight

5825.5424

Sequence

(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Asp Lys Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19)

Type

Peptide

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01801  Insulin analog
   DG01796  Insulin analog, fast-acting
Metabolizing enzyme inducer
DG01637  CYP1A2 inducer

Remark

Therapeutic category:

2492

ATC code:

A10AB05 A10AD05

Product:

D04475<JP/US>

Product (mixture):

D10570<JP>

Efficacy

Antidiabetic, Insulin receptor agonist

Disease

Diabetes mellitus [DS:H00408 H00409]

Comment

insulin analog

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

hsa04930

Type II diabetes mellitus

Interaction

CYP induction: CYP1A2 [HSA:1544]

Structure map

map07051

Antidiabetics

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AB Insulins and analogues for injection, fast-acting
     A10AB05 Insulin aspart
      D04475  Insulin aspart (USP/INN) <JP/US>
    A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
     A10AD05 Insulin aspart
      D04475  Insulin aspart (USP/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
  Insulins
   Insulin, Rapid-acting
    Insulin Aspart
     D04475  Insulin aspart (USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D04475  Insulin aspart (USP/INN); Insulin aspart (genetical recombination) (JP18); Insulin aspart (genetical recombination) [Insulin aspart biosimilar 1] (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04475  Insulin aspart (USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
  D04475  Insulin aspart (genetical recombination)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D04475
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D04475
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D04475
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D04475
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D04475

Other DBs

CAS:	116094-23-6

PubChem:

17398122

LinkDB

» Japanese version » Back

DRUG: Insulin lispro

Entry

D04477 Drug

Name

Insulin lispro (USP/INN);
Insulin lispro (genetical recombination) (JAN);
Insulin lispro (genetical recombination) [Insulin lispro Biosimilar 1] (JAN);
Insulin lispro-aabc;
Humalog (TN);
Lyumjev (TN)

Product

INSULIN LISPRO (A-S Medication Solutions), HUMALOG (A-S Medication Solutions), HUMALOG (A-S Medication Solutions), HUMALOG (A-S Medication Solutions), INSULIN LISPRO (Eli Lilly and Company), HUMALOG (Eli Lilly and Company), HUMALOG (Eli Lilly and Company), HUMALOG (Eli Lilly and Company), INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION (Eli Lilly and Company), INSULIN LISPRO (REMEDYREPACK), INSULIN LISPRO (REMEDYREPACK), HUMALOG (REMEDYREPACK), HUMALOG (REMEDYREPACK), ADMELOG (Sanofi-Aventis U.S. LLC), LYUMJEV (Eli Lilly and Company)

Formula

C257H383N65O77S6

Exact mass

5803.6376

Mol weight

5807.5702

Sequence

(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Lys Pro Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19)

Type

Peptide

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01801  Insulin analog
   DG01796  Insulin analog, fast-acting
Metabolizing enzyme inducer
DG01637  CYP1A2 inducer

Remark

Therapeutic category:

2492

ATC code:

A10AB04 A10AC04 A10AD04

Product:

D04477<JP/US>

Efficacy

Antidiabetic, Insulin receptor agonist

Disease

Diabetes mellitus [DS:H00408 H00409]

Comment

Insulin analog

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

hsa04930

Type II diabetes mellitus

Interaction

CYP induction: CYP1A2 [HSA:1544]

Structure map

map07051

Antidiabetics

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AB Insulins and analogues for injection, fast-acting
     A10AB04 Insulin lispro
      D04477  Insulin lispro (USP/INN) <JP/US>
    A10AC Insulins and analogues for injection, intermediate-acting
     A10AC04 Insulin lispro
      D04477  Insulin lispro (USP/INN) <JP/US>
    A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
     A10AD04 Insulin lispro
      D04477  Insulin lispro (USP/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
  Insulins
   Insulin, Rapid-acting
    Insulin Lispro
     D04477  Insulin lispro (USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D04477  Insulin lispro (USP/INN); Insulin lispro (genetical recombination) (JAN); Insulin lispro (genetical recombination) [Insulin lispro Biosimilar 1] (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04477  Insulin lispro (USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D04477
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D04477
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D04477

Other DBs

CAS:	133107-64-9

PubChem:

17398123

DrugBank:

DB00046

LinkDB

» Japanese version » Back

DRUG: Insulin detemir

Entry

D04539 Drug

Name

Insulin detemir (USAN/INN);
Insulin detemir (genetical recombination) (JAN);
Levemir (TN)

Product

LEVEMIR (A-S Medication Solutions), LEVEMIR (A-S Medication Solutions), LEVEMIR (Novo Nordisk)

Formula

C267H402N64O76S6

Exact mass

5912.7883

Mol weight

5916.822

Sequence

(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro
Lys-C14H27O
(Disulfide bridge: A6-A11, A7-B7, A20-B19)

Type

Peptide

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01801  Insulin analog
   DG01797  Insulin analog, long-acting
Metabolizing enzyme inducer
DG01637  CYP1A2 inducer

Remark

Therapeutic category:

2492

ATC code:

A10AE05

Product:

D04539<JP/US>

Efficacy

Antidiabetic, Insulin receptor agonist

Disease

Diabetes mellitus [DS:H00408 H00409]

Comment

Insulin analog

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

hsa04930

Type II diabetes mellitus

Interaction

CYP induction: CYP1A2 [HSA:1544]

Structure map

map07051

Antidiabetics

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AE Insulins and analogues for injection, long-acting
     A10AE05 Insulin detemir
      D04539  Insulin detemir (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
  Insulins
   Insulin, Long-acting
    Insulin Detemir
     D04539  Insulin detemir (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D04539  Insulin detemir (USAN/INN); Insulin detemir (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04539  Insulin detemir (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D04539
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D04539
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D04539
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D04539
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D04539

Other DBs

CAS:	169148-63-4

PubChem:

17398128

NIKKAJI:

J2.337.674A

LinkDB

» Japanese version » Back

DRUG: Insulin glulisine

Entry

D04540 Drug

Name

Insulin glulisine (USAN/INN);
Insulin glulisine (genetical recombination) (JAN);
Apidra (TN)

Product

INSULIN GLULISINE (sanofi-aventis U.S. LLC)

Formula

C258H384N64O78S6

Exact mass

5818.6373

Mol weight

5822.5816

Sequence

(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19)

Type

Peptide

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01801  Insulin analog
   DG01796  Insulin analog, fast-acting
Metabolizing enzyme inducer
DG01637  CYP1A2 inducer

Remark

Therapeutic category:

2492

ATC code:

A10AB06

Product:

D04540<JP/US>

Efficacy

Antidiabetic, Insulin receptor agonist

Disease

Diabetes mellitus [DS:H00408 H00409]

Comment

Insulin analog
Treatment of type 1 and type 2 diabetes

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

hsa04930

Type II diabetes mellitus

Interaction

CYP induction: CYP1A2 [HSA:1544]

Structure map

map07051

Antidiabetics

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AB Insulins and analogues for injection, fast-acting
     A10AB06 Insulin glulisine
      D04540  Insulin glulisine (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
  Insulins
   Insulin, Rapid-acting
    Insulin Glulisine
     D04540  Insulin glulisine (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D04540  Insulin glulisine (USAN/INN); Insulin glulisine (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04540  Insulin glulisine (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D04540
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D04540
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D04540
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D04540
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D04540

Other DBs

CAS:	207748-29-6

PubChem:

47206386

LinkDB

» Japanese version » Back

DRUG: Insulin human, isophane

Entry

D04541 Mixture Drug

Name

Insulin human, isophane (USP)

Component

Insulin human [DR:D03230], Isophane insulin [DR:D04547]

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01802  Human insulin
   DG01799  Human insulin, intermediate-acting

Efficacy

Antidiabetic, Insulin receptor agonist

Comment

Component of Humulin 70/30 (TN)

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

Interaction

Structure map

map07051

Antidiabetics

Brite

Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04541  Insulin human, isophane (USP)

Other DBs

PubChem:

47206387

LinkDB

» Japanese version » Back

DRUG: Insulin, isophane

Entry

D04547 Drug

Name

Insulin, isophane (USP);
Isophane insulin human (genetical recombination) injectable aqueous suspension (JP18);
Isophane insulin (aqueous suspension) (JAN);
Humalog PEN (TN)

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01802  Human insulin
   DG01799  Human insulin, intermediate-acting
Metabolizing enzyme inducer
DG01637  CYP1A2 inducer

Efficacy

Antidiabetic, Insulin receptor agonist

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

Interaction

CYP induction: CYP1A2 [HSA:1544]

Structure map

map07051

Antidiabetics

Brite

Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04547  Insulin, isophane (USP)
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
  D04547  Isophane insulin human (genetical recombination) injectable aqueous suspension
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D04547

Other DBs

CAS:	53027-39-7

PubChem:

17398129

LinkDB

» Japanese version » Back

DRUG: Insulin degludec

Entry

D09727 Drug

Name

Insulin degludec (USAN/INN);
Insulin degludec (genetical recombination) (JAN);
Tresiba (TN)

Product

TRESIBA (A-S Medication Solutions)

Formula

C274H411N65O81S6

Exact mass

6099.8364

Mol weight

6103.972

Sequence

(A chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys
(Amide bridge: 29-C)
(B chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(Disulfide bridge: 6-11, A7-B7, A19-B20)
(C chain)

Type

Peptide

Class

Antidiabetic agent
DG01636  Insulin and analog
  DG01801  Insulin analog
   DG01797  Insulin analog, long-acting

Remark

Therapeutic category:

2492

ATC code:

A10AE06

Product:

D09727<JP/US>

Product (mixture):

D10570<JP> D11567<JP>

Efficacy

Antidiabetic, Insulin receptor agonist

Disease

Diabetes mellitus [DS:H00408 H00409]

Comment

Insulin analog
Treatment of diabetes

Target

INSR (CD220) [HSA:3643] [KO:K04527]

Pathway

hsa04910

Insulin signaling pathway

hsa04930

Type II diabetes mellitus

Interaction

Structure map

map07051

Antidiabetics

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AE Insulins and analogues for injection, long-acting
     A10AE06 Insulin degludec
      D09727  Insulin degludec (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
  Insulins
   Insulin, Long-acting
    Insulin Degludec
     D09727  Insulin degludec (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D09727  Insulin degludec (USAN/INN); Insulin degludec (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D09727  Insulin degludec (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D09727
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D09727
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D09727
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D09727

Other DBs

CAS:	844439-96-9

PubChem:

124490467

LinkDB

» Japanese version » Back

DBGET integrated database retrieval system